TCG Crossover, which brands itself TCGX, describes itself as "an investment firm focused on innovative biotech companies" that aims to "invest in visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines", with emphasis on the "translation of cutting-edge science into products that will make a meaningful difference for patients". It states that it runs "closed-end funds which means we do not face redemption pressure", and that it helps companies with "pipeline opportunities, navigate the capital markets, execute geographic expansions". It maintains a Science Network the firm says includes "Nobel Prize and Lasker Award recipients", and its stated philosophy is that "drug development is a team sport". These are the firm's own claims. It has offices in Palo Alto, San Francisco and New York City and says it has supported companies in North America, Europe and China. Its 2021 launch release framed the strategy as "investing in companies seeking crossover or public financing".